RTP Mobile Logo
Select Publications

Brufsky A et al. A Phase 2 study of poziotinib in patients with HER2-positive metastatic breast cancer heavily pre-treated with HER2-targeted therapy. SABCS 2020;Abstract PD1-07.

Cort├ęs J et al. Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study. ESMO 2021;Abstract LBA1.

Curigliano G et al. Updated results of tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB). ASCO 2021;Abstract 1043.

Hurvitz SA et al. Efficacy of neratinib plus capecitabine in the subgroup of patients with central nervous system involvement from the NALA trial. Oncologist 2021;26(8):e1327-38. Abstract

Hyder T et al. Aromatase inhibitor-associated musculoskeletal syndrome: Understanding mechanisms and management. Front Endocrinol (Lausanne) 2021;12:713700. Abstract

Jerusalem GH et al. Trastuzumab deruxtecan (T-DXd) in patients with HER2+ metastatic breast cancer with brain metastases: A subgroup analysis of the DESTINY-Breast01 trial. ASCO 2021;Abstract 526.

Lundstrom K et al. Viewpoint: Origin of SARS-CoV-2. Viruses 2020;12(11):1203. Abstract

Mamounas EP et al. Breast Cancer Index (BCI) and prediction of benefit from extended aromatase inhibitor (AI) therapy (tx) in HR+ breast cancer: NRG oncology/NSABP B-42. ASCO 2021;Abstract 501.

Marx GM et al. Dose escalation for mitigating diarrhea: Ranked tolerability assessment of anti-diarrheal regimens in patients receiving neratinib for early-stage breast cancer. ASCO 2021;Abstract 536.

Modi S et al. Updated results from DESTINY-breast01, a phase 2 trial of trastuzumab deruxtecan (T-DXd ) in HER2 positive metastatic breast cancer. SABCS 2020;Abstract PD3-06.

Perrot L et al. First flare of ACPA-positive rheumatoid arthritis after SARS-CoV-2 infection. Lancet Rheumatol 2021;3(1):e6-8. Abstract

Redwan EM et al. The mechanism behind flaring/triggering of autoimmunity disorders associated with COVID-19. Autoimmun Rev 2021;20(10):102909. Abstract